Hepatitis A Vaccine Market Size Regional Insights and Analysis

The hepatitis A vaccine market, valued at $742.31 million in 2023, is projected to grow to $948.16 million by 2034, with a compound annual growth rate (CAGR) of 2.25% from 2024 to 2034. This growth is driven by increasing hepatitis A outbreaks, rising awareness about immunization, and growth in global travel.

Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5301

Market Overview: Hepatitis A Vaccine and Its Role in Immunity

The hepatitis A vaccine provides protection against hepatitis A, a contagious liver infection caused by the hepatitis A virus. The vaccine is typically administered to children between 12–23 months as part of routine immunizations. The CDC recommends hepatitis A vaccination for people with chronic liver disease, those receiving clotting factor treatments, individuals working in high-risk environments, and those living in areas with outbreaks. Vaccination is effective for at least 20 years and possibly a lifetime.

Growing hepatitis A outbreaks, alongside increased cases of HIV and chronic liver disease, drive demand for the vaccine. According to the WHO, hepatitis A affects an estimated 354 million people globally and causes approximately 1.3 million deaths annually. Additionally, supportive government policies and WHO guidelines for vaccination further boost market growth.

Hepatitis A Vaccine Market Trends

In April 2023, Sanofi launched Avaxim Junior, an inactive hepatitis A vaccine for children ages 12 months to 15 years in the UK. Clinical trials conducted across 14 countries showed an effective response in 95% of individuals within two weeks. GlaxoSmithKline (GSK) also reported strong performance, with vaccine sales growing by 25% in 2023 and total sales of £30.3 billion, contributing to an operating profit of £6.7 billion.

Opportunities in the Market: Increased Travel and Tourism

Hepatitis A spreads through food or water contaminated by the feces of an infected person, commonly due to inadequate sanitation or poor hygiene. Travelers to regions with a high prevalence of hepatitis A, such as Africa, Eastern Europe, and Asia, are particularly at risk. In 2023, an estimated 1.3 billion international arrivals were reported, with high activity in the Middle East, Europe, and Africa. The CDC advises that infants 6–11 months old traveling outside the US receive a hepatitis A vaccine dose, while frequent travelers are encouraged to be vaccinated.

Challenges in Manufacturing

Manufacturing hepatitis A vaccines is complex and costly, requiring advanced technology and infrastructure. Scaling up production to meet global healthcare needs while minimizing environmental impact is a significant challenge. Additionally, the manufacturing process requires large quantities of antibodies, viral vectors, and pathogens. The cold chain logistics for vaccine components also complicate the production and distribution process.

Regional Insights

Asia-Pacific: This region led the market in 2023, driven by a high incidence of hepatitis A, supportive government policies, growing investments and partnerships, and increasing public awareness. India reported over 2,400 confirmed cases and 18 deaths by May 2024, while China reported 975 cases as of January 2024. China, a major producer of live attenuated hepatitis A vaccines, represents one of the highest demands for the vaccine globally, accounting for 22% of the total demand according to the WHO.

North America: North America is expected to show the fastest growth during the forecast period. The presence of key players, advanced manufacturing facilities, and supportive government policies contribute to this growth. The US is home to leading hepatitis A vaccine manufacturers, including GSK, Johnson & Johnson, and Merck. The Canadian government provides free hepatitis A vaccinations to high-risk groups, with guidance from the National Advisory Committee on Immunization (NACI), which supports market expansion in the region.

Discover our detailed Table of Contents (TOC) for the Industry, providing a thorough examination of market segments, material, emerging technologies and key trends. Our TOC offers a structured analysis of market dynamics, emerging innovations, and regional dynamics to guide your strategic decisions in this rapidly evolving healthcare field – https://www.towardshealthcare.com/table-of-content/hepatitis-a-vaccine-market-sizing

To own our research study instantly, Click here @ https://www.towardshealthcare.com/price/5301

You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com

About Us

Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations. We are a global strategy consulting firm that assists business leaders in gaining a competitive edge and accelerating growth. We are a provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations.

Explore the comprehensive statistics and insights on healthcare industry data and its associated segmentation: Get a Subscription

For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare